{"groups":[{"description":"Participants received rituximab 1 g intravenously (IV) on Days 1 and 15 of each course of retreatment. In addition, participants received methotrexate 10-25 mg/week orally or parenterally, methylprednisolone 100 mg IV 30 minutes prior to both rituximab infusions, and a stable dose of folic acid ≥ 5 mg/week or equivalent, given as either a single dose or as divided daily doses.","id":"FG000","title":"Rituximab"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"25"}],"type":"Adverse Event"},{"reasons":[{"groupId":"FG000","numSubjects":"16"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"14"}],"type":"Failure to Return"},{"reasons":[{"groupId":"FG000","numSubjects":"27"}],"type":"Administrative/Other"},{"reasons":[{"groupId":"FG000","numSubjects":"96"}],"type":"Reason Not Specified"}],"milestones":[{"achievements":[{"comment":"Six participants did not receive any treatment and were not included in any analyses.","groupId":"FG000","numSubjects":"335"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"157"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"178"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}